Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Sold by Allspring Global Investments Holdings LLC

Allspring Global Investments Holdings LLC reduced its holdings in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 30.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 38,799 shares of the company’s stock after selling 17,152 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Amneal Pharmaceuticals were worth $323,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Rothschild Investment LLC acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $26,000. DekaBank Deutsche Girozentrale acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $42,000. Atlanta Consulting Group Advisors LLC acquired a new stake in Amneal Pharmaceuticals in the first quarter valued at approximately $61,000. nVerses Capital LLC acquired a new stake in Amneal Pharmaceuticals in the second quarter valued at approximately $62,000. Finally, Bayesian Capital Management LP acquired a new stake in Amneal Pharmaceuticals in the first quarter valued at approximately $65,000. 31.82% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Truist Financial raised their price objective on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the company a “buy” rating in a report on Wednesday, October 2nd. Barclays lifted their price target on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a research note on Tuesday, August 13th. Finally, JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 price target on the stock in a research note on Friday, September 6th. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $9.40.

Amneal Pharmaceuticals Stock Up 0.2 %

Shares of NASDAQ:AMRX opened at $8.49 on Friday. The business’s 50 day moving average price is $8.54 and its 200-day moving average price is $7.44. Amneal Pharmaceuticals, Inc. has a 1 year low of $3.91 and a 1 year high of $8.95.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Friday, August 9th. The company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.11 by $0.04. The company had revenue of $701.78 million for the quarter, compared to analyst estimates of $657.43 million. Amneal Pharmaceuticals had a positive return on equity of 1,235.03% and a negative net margin of 6.72%. As a group, equities research analysts anticipate that Amneal Pharmaceuticals, Inc. will post 0.52 EPS for the current year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.